-Hartwig Medical Foundation, a pioneer in deploying complete genomic profiling to improve oncology outcomes, and Ultima Genomics, a developer of a revoluti...
Leveraging dsm-firmenich’s high quality GMP CBD active pharmaceutical ingredient (API) and leading-edge formulation capabilities, chiefly its bioavai...
The facilities, located in Solna, Stängnäs, Höganäs, Karlskoga, and Uppsala OTC Development in Sweden, Pessac in France...
Genmab A/S (Nasdaq: GMAB) and ProfoundBio, Inc. have officially announced a definitive agreement for Genmab's acquisition of ProfoundBio in an all-cash dea...
Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company specializing in allosteric modulation-based drug development,...
The Global Alzheimer's Platform Foundation® (GAP) has announced that Scotland will host the Bio-Hermes Biomarker Data Challenge 2024, a groundb...
Gilles Besin, Ph.D., CSO at Orbital: “Elegen's unique expertise in supplying...IVT-ready synthetic DNA constructs is very attractive ...
Matthias Heinzel, Member of the Executive Board of Merck and CEO Life Science, emphasized the strategic importance of this move, stating, "The Asia...
The completion of Cohort 3 marks a significant milestone, with six participants receiving therapy with 67Cu-SAR-bisPSMA at the highest sing...
Agreement pairs Norgine’s commercial expertise and leading European footprint with PEDMARQSI®, the first and only approved therapy in the Europea...
Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company specializing in endocrine diseases and tumors, revealed encouraging...
New Phase 2b results for amlitelimab support potential for best-in-class maintenance of response in atopic dermatitis Late-breaking dat...
Oxford Nanopore Technologies announced the early access launch of its all-in-one desk top sequencing device, the PromethION 2 Integrated (P2i) to complete ...
GMP material to be used in Phase Ib study in platinum-resistant ovarian cancer (PROC) patients scheduled to start this year. Previously reported Phase I sa...
© 2025 Biopharma Boardroom. All Rights Reserved.
